I’ll start with the overview and recommendations regarding Lp(a) as a risk factor #KnowLpa National Lipid Association

Stumbled on this 💎on Sinus Bradycardia by Reza RLR 104
The EKG don’t LIDE (lie tho) 🤣laughed but it works

Lytes- K/Mg/Ca
Ischemia- affecting Sinus/AV node
Infiltration- conduction disease (ex sarcoid, but more likely AV block)
Drugs, supplements
Endocrinopathy (TSH)

It’s called an ID consult and we exist

Excited to present GradyHealth data at #ACC24 on HF outcomes in HFpEF pts with DM on a GLP-1. Important real world data in a diverse cohort supporting the findings of the STEP-HFpEF DM trial!

All possible through the incredible mentorship of Modele Ogunniyi, MD, MPH and #ORG !
American College of Cardiology

Really cool work led by Aamir Javaid, MD using artificial intelligence to analyze public perceptions of GLP1s on social media

Being presented now at #ACC24

The Osler Medical Residency Johns Hopkins Ciccarone Center Francoise Marvel, MD Roger Blumenthal

Excited to present our work on trends of palliative care utilization in patients with 🫀HFpEF. While there’s an ⬆️ trend in #palliative care use, significant racial, ethnic, and geographic #disparities exist! #ACC24 #HealthEquity Shahzad Hassan Tracy TM, MD, MPH Haider Warraich Jose L. Lopez, MD

So proud of my mentee, Dr. David Annakie presenting his first of many future posters at ACC. #futurecardiologist #memtoringmatters Emory Department of Medicine Association of Black Cardiologists Modele Ogunniyi, MD, MPH Nicole Guynn Nidhi Patel Emory IM Chiefs Gina Lundberg MD FACC FAHA

Thankful for the opportunity to discuss how to improve South Asian 🫀 health starting with considering different imaging modalities for screening in this high risk population. Thank you The Lundquist Institute and UCLA Internal Medicine Chief Residents! Excited to continue more work in this space! #ACC24

Astonishing results from the DanGer Shock Trial presented at #ACC24 and out in NEJM today.

In patients with ST-elevation MI with cardiogenic shock, Impella reduced all-cause mortality (45.8% Impella vs. 58.5% control) at 180 days.

Some thoughts on this ground breaking trial:

Turn those abstracts into manuscripts

Don’t let them end up here … #ACC24

Submit them to ⁦JACC Journals⁩

Best part of ACC, hanging out with the best co-residents Emory Department of Medicine and new friend from UF General Internal Medicine

In EMPACT-MI, a randomized trial involving 6522 patients post-acute myocardial infarction, empagliflozin did not significantly reduce the combined outcome of heart failure hospitalization or death compared to placebo over a period of 17.9 months.

Once again, a drug that…

EMPACT-MI trial: Among patients hospitalized for acute myocardial infarction and at risk for heart failure, empagliflozin did not lead to a significantly lower risk of a first heart-failure hospitalization or death from any cause than placebo. nej.md/4cEb6EB

#ACC24

Excited to kick off ACC watching Esha Dave ⭐️future med student, present her work showing women with coronary vascular dysfunction have ⬆️prevalence of adverse pregnancy outcomes (preeclampsia, gestational DM etc)! Imp implications for risk reduction after 🤰🫀Puja K. Mehta, MD

Extremely honored to continue working with the best nerdiest group out there- not a day without learning new things to better treat our patients 🥳🤓💙 Thank you María Jimena Alemán (ella/she/her) Rabih Geha Reza Madellena (Maddy) Conte Sharmin Shekarchian (@ Jack)

Feel so grateful to be able to present a very special case to two clinicians that I respect so so much, along with a group of amazing people The Clinical Problem Solvers
Thank you Madellena (Maddy) Conte for helping me flesh out this story

Optimizing GDMT for patients with heart failure using digital health remote management system.

jacc.org/doi/10.1016/j.…